Compare Amphastar Pharmaceuticals Inc (AMPH) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs PulteGroup, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.35 (market cap $826.08M), while PulteGroup, Inc. trades at $123.04 (market cap $23.76B). The key difference: PulteGroup, Inc. is far larger — about 28.8× Amphastar Pharmaceuticals Inc's market cap, and PulteGroup, Inc. pays a 0.83% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | PHM | |
|---|---|---|
Market Cap | $826.08M | $23.76B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $142.56 |
52-Week Low | $16.87 | $108.00 |
Enterprise Value | $1.22B | $23.72B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
PulteGroup (PHM) trades at $124.75, up 0.83% on the day, with a bearish technical signal despite recent price strength. The stock shows mixed earnings performance with Q3 2025 beating estimates but subsequent quarters missing, while maintaining solid profitability with a 12.14% net margin. Recent news highlights new community developments and sector attention, though technical indicators suggest caution with RSI at neutral levels and key resistance at $125.
The outlook for PHM is balanced; analyst consensus targets $150.60 (21% upside) with 45% buy ratings, but near-term risks include margin pressure and housing market volatility. Earnings growth remains the key catalyst for sustained upside, while macroeconomic factors pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
